- Global Pharma News & Resources

Anaplastic Astrocytoma Treatment Market Current Scenario 2020 – Global Size, Trends, Growth By Top Leaders, Dynamic, Business Opportunity and Challenges From Up to 2026

SEATTLE, March 24, 2021, (PHARMIWEB) — Global Anaplastic Astrocytoma Treatment Market

Anaplastic astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. The disease has been categorized into four different groups, namely, Grade I, Grade II, Grade III, and Grade IV, based on the reproduction rate of the cells, and their ability to spread over nearby tissues. Grade I and Grade II astrocytomas are non-malignant, and can be referred to as low grade astrocytomas. While, on the other hand, Grade III and Grade IV are malignant, and are known as high grade astrocytomas. With time, the lower grade astrocytoma can change to high grade astrocytomas. However, Grade III astrocytomas are also known as anaplastic astrocytomas.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

Anaplastic Astrocytoma is further categorized into – IDH-mutant and IDH-wildtype. IDH1 is a gene that encodes for a metabolic enzyme called isocitrate dehydrogenase 1. According to the American Brain Tumor Association, about 25,000 new cases of primary malignant brain tumors were diagnosed in the U.S. in 2016. Moreover, over 50% of glioma cases turned out to be glioblastomas. Occurrence of anaplastic astrocytomas is more common in adults than in children, as reported by the same source.

Global Anaplastic Astrocytoma Treatment Market Dynamics

Increasing number of drug candidates in the pipeline, which may receive regulatory approvals over the forecast period, is expected to fuel the global anaplastic astrocytoma treatment market growth. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc., is currently undergoing the Phase 1 clinical trials. The drug has also been granted orphan drug designation (ODD) for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017. Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, called temozolomide.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Anaplastic Astrocytoma Treatment Market Research Report:

Presently, there exist three main forms of treatment for anaplastic astrocytoma – surgery, radiation, and chemotherapy. Of these, surgery is regarded as the first line of treatment in most cases. Only if, whole tumor cannot be safely excised or removed, patients are advised to go for other method of treatment. This treatment pattern, i.e. drugs as second or third line of treatment, has hampered the sales of pharmaceutical drugs, such as Temodar, which in turn, has restrained the growth of the global anaplastic astrocytoma treatment market.

Global Anaplastic Astrocytoma Treatment Market – Regional Outlook

North America is expected to account for major share in global anaplastic astrocytoma treatment market, owing to higher awareness about rare diseases such as anaplastic astrocytoma, and also, presence of leading clinical-stage companies in the region. For instance, a study sponsored by Burzynski Research Institute, headquartered at Texas, U.S., is testing antineoplaston therapy (atengenal + astugenal) in clinical trials. The study is currently in phase 2 clinical trials. Furthermore, a clinical trial sponsored by Northwell Health in collaboration with Genentech, Inc. (subsidiary of Roche AG) is testing safety and efficacy of Erlotinib for anaplastic astrocytoma. The study is currently in Phase 1/2. Approval of these pipeline products over the forecast period would boost growth of North America anaplastic astrocytoma treatment market.

Moreover, the approval of generics for temozolomide will play a vital role in increasing adoption of drug, especially in emerging economies in regions such as Asia Pacific and Latin America. In 2016, FDA approved the Amerigen Pharmaceuticals Limited’s generic version of Temodar. The company’s main facility is in Jiangsu Province, China. The leading global generic players, including Mylan N.V. have received approval for generic version of Temodar in July 2016. The entry of generic drugs is expected to support growth of the anaplastic astrocytoma treatment market.

To understand Research Methodology, please click

Global Anaplastic Astrocytoma Treatment Market – Competititve Scenario

The leading players operating in the global anaplastic astrocytoma treatment market are Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Pfizer, Inc., Perrigo Company Plc, Novartis AG, and Roche AG.

Global Anaplastic Astrocytoma Treatment Market Taxonomy

By Product Type:

  • Alkylating Agents
  • Kinase Inhibitors
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geography:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Table of Content

Global Anaplastic Astrocytoma Treatment Market Research Report
Section 1: Global Anaplastic Astrocytoma Treatment Industry Overview
Section 2: Global Economic Impact on Anaplastic Astrocytoma Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Anaplastic Astrocytoma Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Anaplastic Astrocytoma Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 24-Mar-2021